Puma Biotechnology, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of products for the treatment of various forms of cancer. Its drug candidates include PB272 (neratinib (oral)) and PB272 (neratinib (intravenous) that are in Phase-III and Phase-II clinical trials for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, and HER2 mutation-positive solid tumors. The company is also developing PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
A jump back inside the low of 2015 should ideally complete the reversion back to the point of control for 2015 (approx 78.40) The minor pullback 4 weeks ago was on very light supply - signalling strength to longs. There was also an absorption candle back in December 2015, signalling attractiveness of prices around the 60 level. I haven't gone to look back (honestly don't really care), but I imagine there was a fundamental event that shook the tree in the short term.
Nice +8% mover this morning Puma jumps after FDA approval of breast-cancer treatment Puma Biotechnology Inc. PBYI, +6.66% jumped as much as 11.5% in late trading Monday after the company announced that the Food and Drug Administration had approved a breast-cancer treatment for medical use. The medicine, which will be marketed as Nerlynx and is expected to hit the market in September, is used after traditional treatment to avoid recurrence of HER2 breast cancer.
